申请人:Wuhan Humanwell Innovative Drug Research and
Development Center Limited Company
公开号:EP3901146A1
公开(公告)日:2021-10-27
Provided is a compound. The compound is a compound represented by formula (A), or a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by formula (A), where R is
R1 and R2 are each independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, C1-C10 alkoxyl, halogen, and -CN; and R3, R4, and R5 are each independently selected from C1-C10 alkyl, C3-C10 cycloalkyl, C1-C10 alkoxyl, halogen, and -CN, under a premise that: if R1 is -CH3, C1, or - CN, R2 is not H, and if R1 is H, R2 is not H, -CN, or -CH3.
本文提供了一种化合物。该化合物是式 (A) 所代表的化合物,或式 (A) 所代表化合物的同分异构体、立体异构体、水合物、溶液、盐或原药,其中 R 是
R1和R2各自独立地选自H、C1-C10烷基、C3-C10环烷基、C1-C10烷氧基、卤素和-CN;以及R3、R4和R5各自独立地选自C1-C10烷基、C3-C10环烷基、C1-C10烷氧基、卤素和-CN,前提是:如果R1是-CH3、C1或-CN,则R2不是H;如果R1是H,则R2不是H、-CN或-CH3。